Two polymorphic forms of Fc receptor III (FcR III) are expressed on human neutrophils. These differ with respect to their apparent molecular masses after digestion with N-glycanase, and with respect to their reactivity with MAb Gran 11 and alloantisera which recognize determinants (NA1 and NA2) of the biallelic neutrophil antigen (NA) system. To determine the molecular basis for this polymorphism we isolated RNA from neutrophils of NAlNAl and NA2NA2 homozygotes and synthesized corresponding cDNAs. cDNAs encoding FcR III were then amplified using the polymerase chain reaction, cloned, and sequenced. The cDNA that encodes FcR III on NAlNAl neutrophils differed from the cDNA that encodes FcR III on NA2NA2 neutrophils at five nucleotides, predicting four amino acid substitutions. As a result, NA1 FcR III has only four potential N-linked glycosylation sites as compared with six in NA2 FcR III. The amino acid substitutions and differences in the number of potential N-linked glycosylation sites probably account for the different forms of neutrophil FcR III observed after digestion with N-glycanase and for the antigenic heterogeneity of this receptor.
Introduction
Receptors on human cells for the Fc regions of IgG immunoglobulins (FcR)' mediate phagocytosis of IgG-coated particles as well as other responses to encounters with antigen-antibody complexes (1, 2) . One of these receptors, FcR III, is expressed on the surfaces of neutrophils, eosinophils, tissue macrophages, natural killer (NK) cells, and a small subset of T lymphocytes (1) (2) (3) (4) (5) . FcR III on human neutrophils is extensively glycosylated (5-7) and polymorphic (8) . After immunoprecipitation from surface-labeled cells of healthy donors and treatment with N-glycanase, neutrophil FcR III appears after SDS-PAGE as either a single 29-kD band, a single 33-kD band, or a combination of 29-and 33-kD bands (8) . These forms of neutrophil FcR III also differ with respect to their reactivity with anti-FcR III MAbs as well as with alloantisera that recognize determinants of the biallelic neutrophil antigen (NA) system (8) . Whereas neutrophils from all individuals are recognized by the anti-FcR III MAb 3G8, only neutrophils that yield the 29-kD band react with MAb Gran 11 and anti-NA 1 alloantibodies. Neutrophils that yield the 33-kD band are recognized by anti-NA2 alloantibodies.
To determine the molecular basis for the polymorphism involving FcR III, we isolated RNA from neutrophils of NAlNAl and NA2NA2 homozygotes and synthesized corresponding cDNAs. cDNAs encoding FcR III were then amplified using the polymerase chain reaction (PCR; 9), cloned, and sequenced. The coding sequences of the cDNAs isolated from NAlNA 1 and NA2NA2 neutrophils differed at five bases, and were found to be identical with the coding sequence of FcR III cDNAs that had been isolated previously from human PBMC (10) (Table I) . The PCR was performed as described previously (9), using a GeneAmp DNA amplification reagent kit (Perkin-Elmer Cetus, Norwalk, CT), 100% of the neutrophil cDNA-mRNA hybrids, 0.1 ,umol each of primers A and B, and 2.5 U Taq DNA polymerase. Reaction mixtures were subjected to 40 cycles of denaturation (94°C for 2 min), annealing (55°C for 2 min), and extension (72°C for 5 min) in a DNA thermal cycler (Perkin-Elmer Cetus). Cloning and sequencing of amplified cDNAs. Amplified cDNAs were digested with Eco RI and Hind III (New England Biolabs, Beverly, MA), electrophoresed on 5% polyacrylamide gels, electroeluted, and cloned into pUC1 18 and pUC 19 plasmids (provided by Dr. Dennis Henner, Genentech, Inc., South San Francisco, CA). Singlestranded templates were prepared using the helper phage, Ml 3K07 (18) , and sequenced by the dideoxynucleotide chain-termination method (19) It should be noted that since the findings described above were reproducible, and since similar cDNAs were never produced from other templates, it is quite unlikely that they represent artifacts of the PCR.
Discussion
To determine the molecular basis for the polymorphism involving neutrophil FcR III we used a recently described strategy for amplifying single-stranded cDNAs prepared from small amounts of unfractionated cellular RNA (20) . The feasibility of using RNA from peripheral blood neutrophils for our studies was suggested by the recent demonstration that human neutrophils constitutively synthesize FcR III (21), and by the observation reported here that these cells contain mRNA transcripts that hybridize with an FcR III cDNA probe (Fig. 1) . Consequently, we isolated RNA from neutrophils ofNAlNA 1 and NA2NA2 homozygotes and synthesized corresponding cDNA-mRNA hybrids. Sequences encoding the different forms of neutrophil FcR III were then amplified using the PCR (Fig. 2) . Directional cloning and sequencing of the amplified cDNAs were facilitated by adding recognition sites for Eco RI and Hind III to the synthetic oligonucleotide primers used in the PCR.
The coding sequence of the cDNA prepared from neutrophil RNA of the NAlNAI homozygote was identical to the coding sequence ofthe FcR III cDNA isolated previously from human PBMC (10), while the coding sequences of the cDNAs prepared from neutrophil RNA of the two NA2NA2 homozygotes were identical to the coding sequence of the FcR III cDNA isolated previously from human placenta (11 which would be expected to encode a protein containing 233 amino acid residues. The deduced amino acid sequence of each revealed a putative leader sequence of -18 residues, four symmetrically arranged cysteine residues surrounded by Iglike domains, and a 2 1-residue hydrophobic domain followed by four hydrophilic residues at the carboxy terminus (10, 1 1). The latter is a common feature ofproteins that are anchored to cell membranes via glucosyl-phosphatidylinositol linkages (22) , and is in accord with the observations that FcR III is readily removed from the surfaces of neutrophils by treatment with phosphatidylinositol-specific phospholipase C (23, 24). As indicated above, the cDNAs that encode NA1 FcR III and NA2 FcR III are identical to cDNAs isolated previously from human PBMC and human placenta, respectively (10, 1 1). However, in neither of the reports describing the isolation of these cDNAs was there any indication that neutrophils of the individuals from whom the PBMC and placental tissue were obtained were examined for reactivity with MAb Gran 11 or with anti-NA alloantisera. Consequently, we can only speculate that the individual from whom the PBMC were obtained was an NA lNA 1 homozygote or an NA INA2 heterozygote, and that the individual from whom the placenta was obtained was an NA2NA2 homozygote or an NA1NA2 heterozygote.
Since placenta and PBMC contain a variety of cell types, it is unknown whether the cDNAs isolated from these sources were derived from neutrophil mRNA. Similarly, although we used highly purified neutrophils as a source of RNA for our studies, and although the RNA contained readily detectable FcR III transcripts (Fig. 1) , we cannot exclude the possibility that the transcripts we amplified were derived from cells other than neutrophils. However, evidence appeared while this report was being revised for publication that the gene that encodes neutrophil FcR III is distinct from the gene that encodes NK cell FcR III (25, 26 (24, 25) . Furthermore, using methods very similar to those described in this report, Ravetch and Perussia (26) (Table III) . As a result of these substitutions, NA I FcR III has only four potential N-linked glycosylation sites as compared with six in NA2 FcR III. These differences in primary structure and resulting posttranslational modifications probably account for the different forms of FcR III observed after partial digestion with N-glycanase, as well as for the antigenic heterogeneity of this receptor.
